|
1
|
Siegel RL, Miller KD and Jemal A: Cancer
statistics, 2015. CA Cancer J Clin. 65:5–29. 2015. View Article : Google Scholar : PubMed/NCBI
|
|
2
|
American Cancer Society, . Cancer Facts
and Figures 2008. American Cancer Society; Atlanta, GA: 2008,
https://www.cancer.org/research/cancer-facts-statistics/all-cancer-facts-figures/cancer-facts-figures-2008.html
|
|
3
|
American Cancer Society, . Cancer Facts
and Figures 2007. American Cancer Society; Atlanta, GA: 2007,
https://www.cancer.org/research/cancer-facts-statistics/all-cancer-facts-figures/cancer-facts-figures-2007.html
|
|
4
|
Von Hoff DD, Evans DB and Hruban RH:
Pancreatic Cancer. 1st. Jones and Bartlett Publishers; Sudbury, MA:
2005
|
|
5
|
Chang DK, Merrett ND and Biankin AV; NSW
Pancreatic Cancer Network, : Improving outcomes for operable
pancreatic cancer: Is access to safer surgery the problem? J
Gastroenterol Hepatol. 23:1036–1045. 2008. View Article : Google Scholar : PubMed/NCBI
|
|
6
|
Glaser KB: HDAC inhibitors: Clinical
update and mechanism-based potential. Biochem Pharmacol.
74:659–671. 2007. View Article : Google Scholar : PubMed/NCBI
|
|
7
|
Gore SD: Combination therapy with DNA
methyltransferase inhibitors in hematologic malignancies. Nat Clin
Pract Oncol. 2 Suppl 1:S30–S35. 2005. View Article : Google Scholar : PubMed/NCBI
|
|
8
|
Issa JP and Byrd JC: Decitabine in chronic
leukemias. Semin Hematol. 42 Suppl 2:S43–S49. 2005. View Article : Google Scholar : PubMed/NCBI
|
|
9
|
Munster PN, Troso-Sandoval T, Rosen N,
Rifkind R, Marks PA and Richon VM: The histone deacetylase
inhibitor suberoylanilide hydroxamic acid induces differentiation
of human breast cancer cells. Cancer Res. 61:8492–8497.
2001.PubMed/NCBI
|
|
10
|
Yang XF, Zhao ZJ, Liu JJ, Yang XH, Gao Y,
Zhao S, Shi S, Huang KQ and Zheng HC: SAHA and/or MG132 reverse the
aggressive phenotypes of glioma cells: An in vitro and vivo study.
Oncotarget. 8:3156–3169. 2017.PubMed/NCBI
|
|
11
|
Brueckner B, Kuck D and Lyko F: DNA
methyltransferase inhibitors for cancer therapy. Cancer J.
13:17–22. 2007. View Article : Google Scholar : PubMed/NCBI
|
|
12
|
Hockly E, Richon VM, Woodman B, Smith DL,
Zhou X, Rosa E, Sathasivam K, Ghazi-Noori S, Mahal A, Lowden PA, et
al: Suberoylanilide hydroxamic acid, a histone deacetylase
inhibitor, ameliorates motor deficits in a mouse model of
Huntington's disease. Proc Natl Acad Sci USA. 100:pp. 2041–2046.
2003; View Article : Google Scholar : PubMed/NCBI
|
|
13
|
Asano T, Yao Y, Zhu J, Li D, Abbruzzese JL
and Reddy SA: The PI 3-kinase/Akt signaling pathway is activated
due to aberrant Pten expression and targets transcription factors
NF-kappaB and c-Myc in pancreatic cancer cells. Oncogene.
23:8571–8580. 2004. View Article : Google Scholar : PubMed/NCBI
|
|
14
|
Burris HA III, Moore MJ, Andersen J, Green
MR, Rothenberg ML, Modiano MR, Cripps MC, Portenoy RK, Storniolo
AM, Tarassoff P, et al: Improvements in survival and clinical
benefit with gemcitabine as first-line therapy for patients with
advanced pancreas cancer: A randomized trial. J Clin Oncol.
15:2403–2413. 1997. View Article : Google Scholar : PubMed/NCBI
|
|
15
|
Rothenberg ML, Moore MJ, Cripps MC,
Andersen JS, Portenoy RK, Burris HA III, Green MR, Tarassoff PG,
Brown TD, Casper ES, et al: A phase II trial of gemcitabine in
patients with 5-FU-refractory pancreas cancer. Ann Oncol.
7:347–353. 1996. View Article : Google Scholar : PubMed/NCBI
|
|
16
|
Casper ES, Green MR, Kelsen DP, Heelan RT,
Brown TD, Flombaum CD, Trochanowski B and Tarassoff PG: Phase II
trial of gemcitabine (2,2′-difluorodeoxycytidine) in patients with
adenocarcinoma of the pancreas. Invest New Drugs. 12:29–34. 1994.
View Article : Google Scholar : PubMed/NCBI
|
|
17
|
Carmichael J, Fink U, Russell RC, Spittle
MF, Harris AL, Spiessi G and Blatter J: Phase II study of
gemcitabine in patients with advanced pancreatic cancer. Br J
Cancer. 73:101–105. 1996. View Article : Google Scholar : PubMed/NCBI
|
|
18
|
Katsushima K, Natsume A, Ohka F, Shinjo K,
Hatanaka A, Ichimura N, Sato S, Takahashi S, Kimura H, Totoki Y, et
al: Targeting the Notch-regulated non-coding RNA TUG1 for glioma
treatment. Nat Commun. 7:136162016. View Article : Google Scholar : PubMed/NCBI
|
|
19
|
Gao Y and Teschendorff AE: Epigenetic and
genetic deregulation in cancer target distinct signaling pathway
domains. Nucleic Acids Res. 45:583–596. 2017. View Article : Google Scholar : PubMed/NCBI
|
|
20
|
Batty N, Malouf GG and Issa JP: Histone
deacetylase inhibitors as anti-neoplastic agents. Cancer Lett.
280:192–200. 2009. View Article : Google Scholar : PubMed/NCBI
|
|
21
|
Flotho C, Claus R, Batz C, Schneider M,
Sandrock I, Ihde S, Plass C, Niemeyer CM and Lübbert M: The DNA
methyltransferase inhibitors azacitidine, decitabine and zebularine
exert differential effects on cancer gene expression in acute
myeloid leukemia cells. Leukemia. 23:1019–1028. 2009. View Article : Google Scholar : PubMed/NCBI
|
|
22
|
Laurenzana A, Petruccelli LA, Pettersson
F, Figueroa ME, Melnick A, Baldwin AS, Paoletti F and Miller WH Jr:
Inhibition of DNA methyltransferase activates tumor necrosis factor
alpha-induced monocytic differentiation in acute myeloid leukemia
cells. Cancer Res. 69:55–64. 2009. View Article : Google Scholar : PubMed/NCBI
|
|
23
|
Egger G, Liang G, Aparicio A and Jones PA:
Epigenetics in human disease and prospects for epigenetic therapy.
Nature. 429:457–463. 2004. View Article : Google Scholar : PubMed/NCBI
|
|
24
|
Han T, Hu H, Zhuo M, Wang L, Cui JJ, Jiao
F and Wang LW: Long non-coding RNA: An emerging paradigm of
pancreatic cancer. Curr Mol Med. 16:702–709. 2016. View Article : Google Scholar : PubMed/NCBI
|
|
25
|
Watanabe Y and Maekawa M: Methylation of
DNA in cancer. Adv Clin Chem. 52:145–167. 2010. View Article : Google Scholar : PubMed/NCBI
|
|
26
|
Bu Q, Cui L, Li J, Du X, Zou W, Ding K and
Pan J: SAHA and S116836, a novel tyrosine kinase inhibitor,
synergistically induce apoptosis in imatinib-resistant chronic
myelogenous leukemia cells. Cancer Biol Ther. 15:951–962. 2014.
View Article : Google Scholar : PubMed/NCBI
|
|
27
|
Lee TG, Jeong EH, Kim SY, Kim HR and Kim
CH: The combination of irreversible EGFR TKIs and SAHA induces
apoptosis and autophagy-mediated cell death to overcome acquired
resistance in EGFR T790M-mutated lung cancer. Int J Cancer.
136:2717–2729. 2015. View Article : Google Scholar : PubMed/NCBI
|
|
28
|
Kumagai T, Wakimoto N, Yin D, Gery S,
Kawamata N, Takai N, Komatsu N, Chumakov A, Imai Y and Koeffler HP:
Histone deacetylase inhibitor, suberoylanilide hydroxamic acid
(Vorinostat, SAHA) profoundly inhibits the growth of human
pancreatic cancer cells. Int J Cancer. 121:656–665. 2007.
View Article : Google Scholar : PubMed/NCBI
|
|
29
|
Liang BY, Xiong M, Ji GB, Zhang EL, Zhang
ZY, Dong KS, Chen XP and Huang ZY: Synergistic suppressive effect
of PARP-1 inhibitor PJ34 and HDAC inhibitor SAHA on proliferation
of liver cancer cells. J Huazhong Univ Sci Technolog Med Sci.
35:535–540. 2015. View Article : Google Scholar : PubMed/NCBI
|
|
30
|
Xing J, Wang H, Xu S, Han P, Xin M and
Zhou JL: Sensitization of suberoylanilide hydroxamic acid (SAHA) on
chemoradiation for human cervical cancer cells and its mechanism.
Eur J Gynaecol Oncol. 36:117–122. 2015.PubMed/NCBI
|
|
31
|
Kumar B, Yadav A, Lang JC, Teknos TN and
Kumar P: Suberoylanilide hydroxamic acid (SAHA) reverses
chemoresistance in head and neck cancer cells by targeting cancer
stem cells via the downregulation of nanog. Genes Cancer.
6:169–181. 2015.PubMed/NCBI
|
|
32
|
Min A, Im SA, Kim DK, Song SH, Kim HJ, Lee
KH, Kim TY, Han SW, Oh DY, Kim TY, et al: Histone deacetylase
inhibitor, suberoylanilide hydroxamic acid (SAHA), enhances
anti-tumor effects of the poly (ADP-ribose) polymerase (PARP)
inhibitor olaparib in triple-negative breast cancer cells. Breast
Cancer Res. 17:332015. View Article : Google Scholar : PubMed/NCBI
|
|
33
|
Liu Z, Tong Y, Liu Y, Liu H, Li C, Zhao Y
and Zhang Y: Effects of suberoylanilide hydroxamic acid (SAHA)
combined with paclitaxel (PTX) on paclitaxel-resistant ovarian
cancer cells and insights into the underlying mechanisms. Cancer
Cell Int. 14:1122014. View Article : Google Scholar : PubMed/NCBI
|
|
34
|
Herrero AB, Rojas EA, Misiewicz-Krzeminska
I, Krzeminski P and Gutiérrez NC: Molecular mechanisms of p53
deregulation in cancer: An overview in multiple myeloma. Int J Mol
Sci. 17:172016. View Article : Google Scholar
|
|
35
|
Lv D, Sun R, Yu Q and Zhang X: The long
non-coding RNA maternally expressed gene 3 activates p53 and is
downregulated in esophageal squamous cell cancer. Tumour Biol.
37:16259–16267. 2016. View Article : Google Scholar
|
|
36
|
Blanco J, Lafuente D, Gómez M, García T,
Domingo JL and Sánchez DJ: Polyvinyl pyrrolidone-coated silver
nanoparticles in a human lung cancer cells: Time- and
dose-dependent influence over p53 and caspase-3 protein expression
and epigenetic effects. Arch Toxicol. 91:651–666. 2017. View Article : Google Scholar : PubMed/NCBI
|
|
37
|
Ramadoss S, Guo G and Wang CY: Lysine
demethylase KDM3A regulates breast cancer cell invasion and
apoptosis by targeting histone and the non-histone protein p53.
Oncogene. 36:47–59. 2017. View Article : Google Scholar : PubMed/NCBI
|
|
38
|
Chang Z, Ju H, Ling J, Zhuang Z, Li Z,
Wang H, Fleming JB, Freeman JW, Yu D, Huang P, et al: Cooperativity
of oncogenic K-ras and downregulated p16/INK4A in human pancreatic
tumorigenesis. PLoS One. 9:e1014522014. View Article : Google Scholar : PubMed/NCBI
|
|
39
|
Amano M, Eriksson H, Manning JC, Detjen
KM, André S, Nishimura S, Lehtiö J and Gabius HJ: Tumour suppressor
p16 (INK4a) - anoikis-favouring decrease in N/O-glycan/cell surface
sialylation by downregulation of enzymes in sialic acid
biosynthesis in tandem in a pancreatic carcinoma model. FEBS J.
279:4062–4080. 2012. View Article : Google Scholar : PubMed/NCBI
|
|
40
|
Qian X, Durkin ME, Wang D, Tripathi BK,
Olson L, Yang XY, Vass WC, Popescu NC and Lowy DR: Inactivation of
the Dlc1 gene cooperates with downregulation of p15INK4b and
p16Ink4a, leading to neoplastic transformation and poor prognosis
in human cancer. Cancer Res. 72:5900–5911. 2012. View Article : Google Scholar : PubMed/NCBI
|
|
41
|
Pare R, Shin JS and Lee CS: Increased
expression of senescence markers p14 (ARF) and p16 (INK4a) in
breast cancer is associated with an increased risk of disease
recurrence and poor survival outcome. Histopathology. 69:479–491.
2016. View Article : Google Scholar : PubMed/NCBI
|
|
42
|
Baruah P, Lee M, Wilson PO, Odutoye T,
Williamson P, Hyde N, Kaski JC and Dumitriu IE: Impact of p16
status on pro- and anti-angiogenesis factors in head and neck
cancers. Br J Cancer. 113:653–659. 2015. View Article : Google Scholar : PubMed/NCBI
|
|
43
|
Zhang Z, Rosen DG, Yao JL, Huang J and Liu
J: Expression of p14ARF, p15INK4b, p16INK4a, and DCR2 increases
during prostate cancer progression. Mod Pathol. 19:1339–1343. 2006.
View Article : Google Scholar : PubMed/NCBI
|
